Oświadczenie o dostępności danych: Wszystkie dane są dostępne u dr. n. med. Dominika Pruskiego, dominik.pruski@icloud.com

Konflikt interesów: Autorzy nie zgłaszają konfliktu interesów


Artykuł stanowi przedruk i tłumaczenie: Przybylski M, Pruski D, Wszołek K, de Mezer M, Żurawski J, Jach R, Millert-Kalińska S. Prevalence of HPV and assessing type-specific HPV testing in cervical high-grade squamous intraepithelial lesions in Poland. Pathogens 2023;12(2):350. doi: 10.3390/pathogens12020350

ABSTRACT

Prevalence of HPV and assessing type-specific HPV testing in cervical high-grade squamous intraepithelial lesions in Poland

The prevalence and distribution of oncogenic human papillomavirus (HPV) genotypes in women who underwent screening for cervical cancer in the Wielkopolska region, Poland, were assessed, and the correlation of genotypes with the histological results was evaluated. Cervical samples were collected from 2969 women for cervical cancer screening. Participants were screened by liquid-based cytology and HPV genotyping (n = 1654) and referred to colposcopy and punch biopsy (n = 616) if recommended. HPV genotypes 16, 31, 52, 66, 53, and 51 are the most frequent types in the studied population. Genotypes 16 and 31 account for nearly one-fifth of the infections of diagnosed HPV infections. HPV 16, 31, and 52 are found in nearly 80% of premalignant HSIL lesions (CIN 2 and CIN 3). That leads to the conclusion that vaccination programs should cover as many types of HPV as possible and shows the urgent need to vaccinate the Polish population with a 9-valent vaccine.

Piśmiennictwo

1. Zur Hausen H. Papillomaviruses in the causation of human cancers – a brief historical account. Virology 2009;384(2):260-5

2. Schneider A. Pathogenesis of genital HPV infection. Genitourin Med 1993;69(3):165-73

3. Völter C, He Y, Delius H, et al. Novel HPV types present in oral papillomatous lesions from patients with HIV infection. Int J Cancer 1996;66(4):453-6

4. Maciag PC, Villa LL. Genetic susceptibility to HPV infection and cervical cancer. Braz J Med Biol Res 1999;32(7):915-22

5. Hillman RJ, Ryait BK, Botcherby M, et al. Changes in HPV infection in patients with anogenital warts and their partners. Genitourin Med 1993;69(6):450-6

6. Löwhagen GB, Bolmstedt A, Ryd W, et al. The prevalence of "high-risk" HPV types in penile condyloma-like lesions: correlation between HPV type and morphology. Genitourin Med 1993;69(2):87-90

7. Jacobs MV, Walboomers JM, Snijders PJ, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000;87(2):221-7

8. Bedell SL, Goldstein LS, Goldstein AR, et al. Cervical cancer screening: past, present and future. Sex Med Rev 2020;8(1):28-37

9. Manini I, Montomoli E. Epidemiology and prevention of human papillomavirus. Ann Ig 2018;30(4 Supple 1):28-32

10. Magalhães GM, Vieira ÉC, Garcia LC, et al. Update on human papilloma virus – part I: epidemiology, pathogenesis and clinical spectrum. An Bras Dermatol 2021;96(1):1-16

11. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012;131(10):2349-59

12. Zhang J, Cheng K, Wang Z. Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China: a meta-analysis. Arch Gynecol Obstet 2020;302(6):1329-37

13. Kiwerska K, Józefiak A, Markowska J, et al. Oral-genital human papillomavirus infection in Polish couples: frequent detection of HPV 42. BMC Infect Dis 2019;19(1):122

14. Chesson HW, Dunne EF, Hariri S, et al. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis 2014;41(11):660-4

15. Soheili M, Keyvani H, Soheili M, et al. Human papilloma virus: a review study of epidemiology, carcinogenesis, diagnostic methods and treatment of all HPV-related cancers. Med J Islam Repub Iran 2021;35:65

16. Gravitt PE, Winer RL. Natural history of HPV infection across the lifespan: role of viral latency. Viruses 2017;9(10):267

17. Shanmugasundaram S, You J. Targeting persistent human papillomavirus infection. Viruses 2017;9(8):229

18. Peng S, Trimble C, Wu L, et al. HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Re 2007;13(8):2479-87

19. Pattyn J, Van Keer S, Tjalma W, et al. Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature. Papillomavirus Res 2019;8:100185

20. Zeppa P. Liquid-based cytology: a 25-year bridge between the pap smear and molecular cytopathology. Acta Cytol 2014;58(6):519-21

21. Von Knebel Doeberitz M, Prigge ES. Role of DNA methylation in HPV associated lesions. Papillomavirus Res 2019;7:180-3

22. Wentzensen N, Schiffman M, Palmer T, et al. Triage of HPV positive women in cervical cancer screening. J Clin Virol 2016;76(Suppl 1):S49-55

23. Tsikouras P, Zervoudis S, Manav B, et al. Cervical cancer: screening, diagnosis and staging. J BUON 2016;21(2):320-5

24. Schiffman M, Kinney WK, Cheung LC, et al. Relative performance of HPV and cytology components of cotesting in cervical screening. J Natl Cancer Inst 2018;110(5):501-8

25. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424

26. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209-49

27. International Transport Forum/Oecd. Human papillomavirus and related cancers fact sheet 2021. Econ. Outlook 2020;14:2005

28. Dyzmann-Sroka A, Bagniewska K, Chyła K i wsp. Dlaczego Wielkopolanki nie robią badań mammograficznych? Raport. Zesz Nauk WCO Lett Oncol Sci 2012;9(4):169-81

29. Wszołek K, Pruski D, Tomczyk K, et al. Women's healthcare services since the COVID-19 pandemic outbreak in Poland. Int J Environ Res Public Health 2021;19(1):180

30. Patel C, Brotherton JM, Pillsbury A, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill 2018;23(41):1700737

31. Colín-Ferreyra MDC, Domínguez-García MV, Mendieta-Zerón H, et al. Genotyping of human papillomavirus in cervical squamous intraepithelial lesions in Mexican women. Jpn J Infect Dis 2020;73(2):157-60

32. García-Espinosa B, Moro-Rodríguez E, Alvarez-Fernández E. Genotype distribution of human papillomavirus (HPV) in histological sections of cervical intraepithelial neoplasia and invasive cervical carcinoma in Madrid, Spain. BMC Cancer 2012;12:533

33. Coutlée F, Ratnam S, Ramanakumar AV, et al. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol 2011;83(6):1034-41

34. Sánchez-Lander J, Cortiñas P, Loureiro CL, et al. Human papillomavirus in invasive cervical cancer and cervical intraepithelial neoplasia 2 and 3 in Venezuela: a cross-sectional study. Cancer Epidemiol 2012;36(5):e284-7

35. Wu D, Cai L, Huang M, et al. Prevalence of genital human papillomavirus infection and genotypes among women from Fujian province, PR China. Eur J Obstet Gynecol Reprod Biol 2010;151(1):86-90

36. Simonella LM, Lewis H, Smith M, et al. Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand. BMC Infect Dis 2013;13:114

37. Shipitsyna E, Zolotoverkhaya E, Kuevda D, et al. Prevalence of high-risk human papillomavirus types and cervical squamous intraepithelial lesions in women over 30 years of age in St. Petersburg, Russia. Cancer Epidemiol 2011;35(2):160-4

38. Pista A, de Oliveira CF, Lopes C, et al.; CLEOPATRE Portugal Study Group. Human papillomavirus type distribution in cervical intraepithelial neoplasia grade 2/3 and cervical cancer in Portugal: a CLEOPATRE II Study. Int J Gynecol Cancer 2013;23(3):500-6

39. Prétet JL, Jacquard AC, Carcopino X, et al.; EDITH study group. Human papillomavirus genotype distribution in high grade cervical lesions (CIN 2/3) in France: EDITH study. Int J Cancer 2008;122(2):424-7

40. Zhang J, Zhang D, Yang Z, et al. The role of human papillomavirus genotyping for detecting high-grade intraepithelial neoplasia or cancer in HPV-positive women with normal cytology: a study from a hospital in northeastern China. BMC Cancer 2020;20(1):443

41. Kędzia W, Pruski D, Józefiak A i wsp. Genotypowanie onkogennych wirusów brodawczaka ludzkiego u kobiet z rozpoznaniem HG SIL. Ginekol Pol 2010;81:664-7

Do góry